Q3 Earnings Estimate for TCRX Issued By Lifesci Capital

Key Points

• Lifesci Capital forecasts TScan Therapeutics will report earnings of ($0.31) per share for Q3 2025, consistent with the projected full-year earnings of ($1.12) per share.
• The company last reported earnings of ($0.28) per share, matching analysts' expectations and generating revenues of $3.08 million, exceeding expectations of $1.31 million.
• TScan Therapeutics currently has a Moderate Buy consensus rating among analysts, with a target price averaging $7.80, while recent price targets range from $7.00 to $10.00.

TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Lifesci Capital issued their Q3 2025 EPS estimates for TScan Therapeutics in a research report issued on Thursday, August 14th. Lifesci Capital analyst S. Slutsky anticipates that the company will earn ($0.31) per share for the quarter. The consensus estimate for TScan Therapeutics' current full-year earnings is ($1.12) per share. Lifesci Capital also issued estimates for TScan Therapeutics' Q4 2025 earnings at ($0.31) EPS.

Several other brokerages have also commented on TCRX. HC Wainwright lowered their price objective on TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Wall Street Zen raised TScan Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, July 12th. Finally, Wedbush reiterated an "outperform" rating and issued a $7.00 price objective on shares of TScan Therapeutics in a report on Tuesday, August 12th. Five analysts have rated the stock with a Buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $7.80.

TScan Therapeutics Trading Up 2.7%

Shares of TCRX stock traded up $0.0450 during mid-day trading on Friday, reaching $1.7250. The stock had a trading volume of 100,642 shares, compared to its average volume of 464,879. TScan Therapeutics has a 52-week low of $1.02 and a 52-week high of $6.2250. The company has a current ratio of 7.06, a quick ratio of 7.06 and a debt-to-equity ratio of 0.18. The stock's 50-day moving average price is $1.68 and its two-hundred day moving average price is $1.65. The firm has a market capitalization of $97.62 million, a PE ratio of -1.58 and a beta of 0.99.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.28). TScan Therapeutics had a negative net margin of 1,964.88% and a negative return on equity of 63.33%. The business had revenue of $3.08 million for the quarter, compared to analysts' expectations of $1.31 million.

Hedge Funds Weigh In On TScan Therapeutics

Several institutional investors have recently bought and sold shares of TCRX. ProShare Advisors LLC bought a new stake in TScan Therapeutics in the 4th quarter worth approximately $40,000. Catalyst Funds Management Pty Ltd bought a new stake in TScan Therapeutics in the second quarter worth about $26,000. Squarepoint Ops LLC purchased a new position in TScan Therapeutics during the 4th quarter valued at $59,000. Wells Fargo & Company MN grew its holdings in shares of TScan Therapeutics by 41.1% in the fourth quarter. Wells Fargo & Company MN now owns 19,540 shares of the company's stock worth $59,000 after purchasing an additional 5,694 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC purchased a new position in TScan Therapeutics in the 2nd quarter worth about $29,000. 82.83% of the stock is owned by hedge funds and other institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.